Cladribine Alternatives Compared
| Cladribine | Kesimpta (ofatumumab) | Copaxone (glatiramer) |
|
|---|
| Cladribine | Kesimpta (ofatumumab) | Copaxone (glatiramer) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hairy Cell Leukemia, Multiple Sclerosis. Cladribine may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
Prescription only
Copaxone is a combination of four amino acids that may be given to treat relapsing forms of multiple sclerosis in adults. It has been shown to significantly reduce the number of relapses but may be... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Cladribine | More about Kesimpta (ofatumumab) | More about Copaxone (glatiramer) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Cladribine has an average rating of 8.0 out of 10 from a total of 10 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 20% reported a negative effect. |
Kesimpta has an average rating of 7.0 out of 10 from a total of 79 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 18% reported a negative effect. |
Copaxone has an average rating of 7.5 out of 10 from a total of 133 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Cladribine side effects |
View all Kesimpta side effects |
View all Copaxone side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Cladribine prices |
View all Kesimpta prices |
View all Copaxone prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Cladribine Novaplus, Mavenclad | Other ofatumumab brands include: Arzerra | Other glatiramer brands include: Glatopa | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
6.7 hours |
1476 hours |
1 hour |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 503 drugs are known to interact with Cladribine:
|
A total of 181 drugs are known to interact with Kesimpta:
|
A total of 1 drugs are known to interact with Copaxone:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
March 29, 2019 |
N/A |
December 20, 1996 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Mavenclad
Mavenclad (cladribine) is used for the treatment of multiple sclerosis. Mavenclad information ...
Kesimpta
Kesimpta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated ...
Intron A
Intron A is used for angioblastoma, condylomata acuminata, conjunctival mucosa-associated lymphoid ...
Lumoxiti
Lumoxiti (moxetumomab pasudotox) is used to treat hairy cell leukemia. Includes Lumoxiti side ...
Zanaflex
Zanaflex (tizanidine) is a short-acting muscle relaxer used to treat spasticity by temporarily ...
Lioresal
Lioresal is used for chronic spasticity, muscle spasm, spasticity, spinal spasticity
Gablofen
Gablofen (baclofen) is used to treat severe spasticity. Includes Gablofen side effects ...
Lyvispah
Lyvispah is used to treat muscle stiffness, spasms, and pain from multiple sclerosis. It may also ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.